Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO, April 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today... | April 12, 2023

Related Keywords

United States ,San Diego ,California ,Jay Hagan ,Regulus Therapeutics Inc ,Rnas The Company Or Regulus ,Nasdaq ,Prnewswire Regulus Therapeutics Inc ,Exchange Commission ,Dominant Polycystic Kidney Disease ,Private Securities Litigation Reform Act ,Regulus Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Han ,Pril ,023 ,Regulus ,Herapeutics ,Iopharmaceutical ,Company ,Ocused ,N ,The ,Discovery ,End ,Development ,F ,Nnovative ,Medicines ,Targeting ,Icrornas Rgls Us75915k3095 ,